Sugi Predict

Sugi Predict / Compounds / SCHEMBL1727042

SCHEMBL1727042

SCHEMBL1727042

Cc1cc(Br)cc(F)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.42
▸ ACHE P22303 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PTGS2 P35354 2/20 0.38
▸ MAPT P10636 1/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ DGAT1 O75907 1/20 0.36
▸ NOTUM Q6P988 1/20 0.35
▸ LDHA P00338 1/20 0.35
▸ LDHB P07195 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GPR17 Q13304 1/20 0.35
▸ FABP3 P05413 1/20 0.34
▸ FABP4 P15090 1/20 0.34
▸ AKR1C4 P17516 1/20 0.34
▸ AKR1C3 P42330 1/20 0.34
▸ AKR1C2 P52895 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29803911 1.00 CYP3A4 (0.42) CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2
SCHEMBL516974 0.85 DGAT1 (0.42) ALDH1A1SMN1; SMN2MAPTDGAT1GPR17
SCHEMBL596184 0.85 CYP3A4 (0.50) CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2
SCHEMBL1725337 0.82 DGAT1 (0.47) ALDH1A1PTGS2MAPTDGAT1HDAC1
SCHEMBL22955911 0.82 DGAT1 (0.35) ALDH1A1MAPK1SMN1; SMN2PTGS2MAPT
SCHEMBL17419113 0.79 CYP3A4 (0.47) CYP3A4ACHEALDH1A1MAPTNOTUM
SCHEMBL286849 0.79 AKR1C4 (0.45) CYP3A4ALDH1A1SMN1; SMN2DGAT1GPR17
SCHEMBL27101128 0.79 CYP3A4 (0.45) CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2
SCHEMBL17831135 0.79 KDM4E (0.48) CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2
SCHEMBL22093028 0.78 AKR1C3 (0.39) CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118652178-A Synthesis method of 4-bromo-2-fluoro-6-methyl benzoate 上海毕得医药科技股份有限公司 2024-09-17 — — CN claimed
CN-115650851-A Preparation method of 2-fluoro-4-bromo-6-methyl benzoate 无锡双启科技有限公司 2023-01-31 — — CN claimed
EP-4739306-A2 POLO-LIKE KINASE 1 INHIBITORS Cervero Therapeutics, LLC (US) 2026-05-13 — — EP disclosed
EP-4724436-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2026-04-15 — — EP disclosed
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2026-03-19 — — US disclosed
EP-4161931-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-02-18 — — EP disclosed
EP-4688771-A1 NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2026-02-11 — — EP disclosed
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 — — WO disclosed
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2025-10-30 — — US disclosed
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-10-14 — — US disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 — — EP disclosed
US-20160207906-A1 NOVEL 2,6-DIAMINOPYRIMIDINE DERIVATIVE CARNA BIOSCIENCES, INC. (JP) 2016-07-21 — — US disclosed
EP-3042899-A1 NOVEL 2,6-DIAMINOPYRIMIDINE DERIVATIVE Carna Biosciences Inc. (JP) 2016-07-13 — — EP disclosed
US-20160168122-A1 NOVEL TRIAZINE DERIVATIVE CARNA BIOSCIENCES, INC. (JP) 2016-06-16 — — US disclosed
EP-3026050-A1 NOVEL TRIAZINE DERIVATIVE Carna Biosciences Inc. (JP) 2016-06-01 — — EP disclosed
US-8299077-B2 Inhibitors of Bruton's tyrosine kinase ROCHE PALO ALTO LLC (US) 2012-10-30 — — US disclosed
EP-2403846-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. Hoffmann-La Roche AG (CH) 2012-01-11 — — EP disclosed
CN-102015674-A Modulators of dopamine neurotransmission NSAB AF NEUROSEARCH SWEDEN AB 2011-04-13 — — CN disclosed
WO-2010100070-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2010-09-10 — — WO disclosed
US-20100222325-A1 Inhibitors of Bruton's Tyrosine Kinase BERTHEL STEVEN 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160207906-A1 NOVEL 2,6-DIAMINOPYRIMIDINE DERIVATIVE DPYD, QDPR, PARP2 CYP3A4 1125/4885ACHE 4750/4885ALDH1A1 303/4885
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN2, SNRPA1 CYP3A4 4564/4885ACHE 4337/4885ALDH1A1 3447/4885
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF CTTN, SRC, PTK2 CYP3A4 3120/4885ACHE 2869/4885ALDH1A1 4164/4885
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect KEAP1, NFE2L2, BACH1 CYP3A4 1503/4885ACHE 2418/4885ALDH1A1 1411/4885
US-20100222325-A1 Inhibitors of Bruton's Tyrosine Kinase BTK, SYK, LYN CYP3A4 3297/4885ACHE 3388/4885ALDH1A1 4625/4885
US-20160168122-A1 NOVEL TRIAZINE DERIVATIVE CBR3, HDAC3, SSTR3 CYP3A4 642/4885ACHE 4058/4885ALDH1A1 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.